Affimed gets FDA fast track status for AFM24 for EGFR lung cancer

Affimed (NASDAQ:AFMD) said it has received fast track designation from the FDA for its drug candidate AFM24 in combination with atezolizumab in the treatment of EGFR wild-type non-small cell lung cancer.

AFM24 in combination with atezolizumab is currently being evaluated in a Phase 1/2 study for the treatment of EGFR wild-type and EGFR mutant advanced/metastatic non-small cell lung cancers, according to Affimed.

Atezolizumab is marketed by Roche as Tecentriq.